keyword
MENU ▼
Read by QxMD icon Read
search

Phase 3 cancer

keyword
https://www.readbyqxmd.com/read/29677217/optimisation-of-three-dimensional-lower-jaw-resection-margin-planning-using-a-novel-black-bone-magnetic-resonance-imaging-protocol
#1
Astrid M Hoving, Joep Kraeima, Rutger H Schepers, Hildebrand Dijkstra, Jan Hendrik Potze, Bart Dorgelo, Max J H Witjes
BACKGROUND: MRI is the optimal method for sensitive detection of tumour tissue and pre-operative staging in oral cancer. When jawbone resections are necessary, the current standard of care for oral tumour surgery in our hospital is 3D virtual planning from CT data. 3D printed jawbone cutting guides are designed from the CT data. The tumour margins are difficult to visualise on CT, whereas they are clearly visible on MRI scans. The aim of this study was to change the conventional CT-based workflow by developing a method for 3D MRI-based lower jaw models...
2018: PloS One
https://www.readbyqxmd.com/read/29675680/a-randomized-double-blind-phase-2-study-of-ruxolitinib-or-placebo-in-combination-with-capecitabine-in-patients-with-advanced-her2-negative-breast-cancer-and-elevated-c-reactive-protein-a-marker-of-systemic-inflammation
#2
Joyce O'Shaughnessy, Angela DeMichele, Cynthia X Ma, Paul Richards, Denise A Yardley, Gail Shaw Wright, Kevin Kalinsky, Ronald Steis, Sami Diab, Gerard Kennealey, Ryan Geschwindt, Wei Jiang, Hope S Rugo
PURPOSE: The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhibitor, to capecitabine in patients with HER2-negative advanced breast cancer and high systemic inflammation (modified Glasgow Prognostic Score [mGPS] ≥ 1). METHODS: Patients with ≤ 2 prior chemotherapy regimens for advanced or metastatic disease or hormone receptor-positive patients with disease progression on prior hormonal therapies were randomized 1:1 to 21-day cycles of ruxolitinib (n = 76) or placebo (n = 73) plus capecitabine...
April 19, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29675095/phase-i-ii-clinical-trial-of-everolimus-combined-with-gemcitabine-cisplatin-for-metastatic-triple-negative-breast-cancer
#3
In Hae Park, Sun-Young Kong, Youngmee Kwon, Min Kyeong Kim, Sung Hoon Sim, Jungnam Joo, Keun Seok Lee
Background: The PI3K/AKT/mTOR pathway is an important oncogenic driver in triple-negative breast cancer (TNBC). This study investigated the clinical efficacy and safety of the combination of gemcitabine and cisplatin with everolimus (GPE) in patients with metastatic TNBC. Methods: In phase I, we assessed the maximum tolerated dose (MTD) of GPE in metastatic TNBC patients. Then, using a seamless design, we conducted a randomized phase II trial to compare GPE to GP in terms of progression-free survival (PFS) and toxicity...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29674428/optimising-endocrine-therapy-in-postmenopausal-women-with-advanced-breast-cancer
#4
Thomas Ho Lai Yau, Kl Cheung
Hormone receptor-positive breast cancer is commonly treated with endocrine therapy; however, overtime cancer cells can develop endocrine resistance. This review aims to document combination therapy and sequential therapy in the use of endocrine agents and targeted agents. By conducting two systematic searches using 4 databases: Cochrane Library, MEDLINE, EMBASE, and Web of Science. A total of 26 studies that covered combination therapy were obtained and included for the review. 14 were phase III documenting combinations of mechanistic target of rapamycin (mTOR), phosphoinositide-3-kinase (PI3K), vascular endothelial growth factor receptor (VEGFR), human epidermal growth factor receptor 2 (HER2), and cyclin dependent kinase 4/6 (CDK4/6) inhibitors...
April 19, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29673361/adding-a-second-surprise-question-triggers-general-practitioners-to-increase-the-thoroughness-of-palliative-care-planning-results-of-a-pilot-rct-with-cage-vignettes
#5
F Weijers, C Veldhoven, C Verhagen, K Vissers, Y Engels
BACKGROUND: In our aging society, palliative care should be a standard component of health care. However, currently it is only provided to a small proportion of patients, mostly to those with cancer, and restricted to the terminal phase. Many general practitioners (GPs) say that one of their most significant challenges is to assess the right moment to start anticipatory palliative care. The "Surprise Question" (SQ1: "Would I be surprised if this patient were to die in the next 12 months"?), if answered with "no", is an easy tool to apply in identifying patients in need of palliative care...
April 19, 2018: BMC Palliative Care
https://www.readbyqxmd.com/read/29673070/mycn-is-a-novel-oncogenic-target-in-adult-b-all-that-activates-the-wnt-%C3%AE-catenin-pathway-by-suppressing-dkk3
#6
Desheng Kong, Linlin Zhao, Lili Sun, Shengjin Fan, Huibo Li, Yanqiu Zhao, Zhibo Guo, Leilei Lin, Lin Cui, Ke Wang, Wenjia Chen, Yihui Zhang, Jin Zhou, Yinghua Li
Dickkopf-3 (DKK3) is frequently down-regulated by promoter hypermethylation and is closely associated with a poor prognosis in many cancers. Our previous studies have shown that miR-708 down-regulates DKK3 at the post-transcriptional level in B-ALL. However, whether transcriptional mechanisms lead to DKK3 silencing remains unclear. Here, we analysed the promoter regions of DKK3 by bioinformatics and found binding sites for MYCN. A dual-luciferase reporter gene assay and ChIP experiments revealed that MYCN negatively regulates DKK3 at the transcriptional level in B-ALL cell lines, and using bisulphite sequencing PCR, we affirmed that MYCN has no effect on the methylation of the DKK3 promoter...
April 19, 2018: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/29671386/k237-modified-thermosensitive-liposome-enhanced-the-delivery-efficiency-and-cytotoxicity-of-paclitaxel-in-vitro
#7
Xudong Fu, Yuanyuan Lu, Jiaping Guo, Hui Liu, Aiping Deng, Changchun Kuang, Xiangyang Xie
This study aimed to develop novel temperature-sensitive liposomes loading paclitaxel (PTX-TSL) and evaluate them in vitro to improve the delivery efficiency and targeting of PTX. K237 peptide was conjugated to the terminal NHS of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[hydroxyl succinimidyl (polyethylene glycol)-(DSPE-PEG-NHS), and K237-modified PTX-TSL (K237-PTX-TSL) was prepared using a film dispersion method. K237-TSL encapsulation with calcein was synthesized and used to determine the cellular uptake of TSL...
April 19, 2018: Journal of Liposome Research
https://www.readbyqxmd.com/read/29670371/knockdown-of-fibrous-sheath-interacting-protein-1-expression-reduces-bladder-urothelial-carcinoma-cell-proliferation-and-induces-apoptosis-via-inhibition-of-the-pi3k-akt-pathway
#8
Ming Sun, Zhaofu Chen, Shutao Tan, Caigang Liu, Wenyan Zhao
Background: FSIP1 plays a vital role in tumorigenesis and cancer progression. In bladder cancer, FSIP1 overexpression was associated with poor prognosis of bladder urothelial carcinoma. In this study, we investigated whether FSIP1 is essential in the progression of bladder cancer and the mechanism by which it mediates this effect. Methods: FSIP1 expression was knocked down in bladder cancer cells using lentiviral-mediated short hairpin RNA (shRNA). FSIP1 expression was detected using Western blotting, immunohistochemistry (IHC), and quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29669701/crizotinib-in-patients-with-advanced-inoperable-inflammatory-myofibroblastic-tumours-with-and-without-anaplastic-lymphoma-kinase-gene-alterations-european-organisation-for-research-and-treatment-of-cancer-90101-create-a-multicentre-single-drug-prospective-non
#9
Patrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, Jean-Yves Blay, Sandra J Strauss, Silvia Stacchiotti, Piotr Rutkowski, Lars H Lindner, Michael G Leahy, Antoine Italiano, Nicolas Isambert, Maria Debiec-Rychter, Raf Sciot, Thomas Van Cann, Sandrine Marréaud, Axelle Nzokirantevye, Sandra Collette, Agnieszka Wozniak
BACKGROUND: An inflammatory myofibroblastic tumour (IMFT) is a rare mesenchymal neoplasm characterised by anaplastic lymphoma kinase (ALK) gene rearrangements. We assessed the activity and safety of crizotinib, a tyrosine kinase inhibitor, targeting ALK in patients with advanced IMFT either with or without ALK alterations. METHODS: We did a multicentre, biomarker-driven, single-drug, non-randomised, open-label, two-stage phase 2 trial (European Organisation for Research and Treatment of Cancer 90101 CREATE) at 13 study sites (five university hospitals and eight specialty clinics) in eight European countries (Belgium, France, Germany, Italy, Netherlands, Poland, Slovakia, and the UK)...
April 12, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29669181/racial-disparity-in-oncologic-and-quality-of-life-outcomes-in-patients-with-locally-advanced-head-and-neck-squamous-cell-carcinomas-enrolled-in-a-randomized-phase-2-trial
#10
Margaret K Guerriero, Mary W Redman, Kelsey K Baker, Renato G Martins, Keith Eaton, Laura Q Chow, Rafael Santana-Davila, Christina Baik, Bernardo H Goulart, Sylvia Lee, Cristina P Rodriguez
BACKGROUND: To better understand patient-reported quality of life (PRQOL) for patients with head and neck cancer, PRQOL scores were collected in a clinical trial. METHODS: Patients were randomized to arm A (70 Gy of radiation with cisplatin) or arm B (70 Gy of radiation with cisplatin plus erlotinib at 150 mg daily). PRQOL scores were measured on days -7 (arm B only), 0, 30, and 180 with the University of Washington Quality of Life Questionnaire. Associations with clinical factors and outcomes were explored with linear mixed, logistic, and Cox regression models...
April 18, 2018: Cancer
https://www.readbyqxmd.com/read/29668860/alectinib-versus-chemotherapy-in-crizotinib-pretreated-anaplastic-lymphoma-kinase-alk-positive-non-small-cell-lung-cancer-results-from-the-phase-iii-alur-study
#11
S Novello, J Mazières, I-J Oh, J de Castro, M R Migliorino, Å Helland, R Dziadziuszko, F Griesinger, A Kotb, A Zeaiter, A Cardona, B Balas, H K Johannsdottir, A Das-Gupta, J Wolf
Background: This is the first trial to directly compare efficacy and safety of alectinib versus standard chemotherapy in advanced/metastatic anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) patients who have progressed on, or were intolerant to, crizotinib. Patients and methods: ALUR (MO29750; NCT02604342) was a randomized, multicenter, open-label, phase III trial of alectinib versus chemotherapy in advanced/metastatic anaplastic lymphoma kinase (ALK)-positive NSCLC patients previously treated with platinum-based doublet chemotherapy and crizotinib...
April 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29667321/the-ethanol-extraction-of-prepared-psoralea-corylifolia-induces-apoptosis-and-autophagy-and-alteres-genes-expression-assayed-by-cdna-microarray-in-human-prostate-cancer-pc-3-cells
#12
Chia-Hsin Lin, Shinji Funayama, Shu-Fen Peng, Chao-Lin Kuo, Jing-Gung Chung
Prostate cancer is the most common male reproductive system cancer. The prevalence of prostate cancer in Europe and the United States is higher than that in the Asian region. However, the treatment of prostate cancer remains unsatisfactory. Psoralea corylifolia has been used to cure this disease as Chinese medicine in the Asian region. In this study, we analyzed the components of ethanol extraction of unprepared and prepared P. corylifolia by HPLC. Psoralen and isopsoralen content from the prepared P. corylifolia is twofold higher than that from unprepared, so we use the prepared extraction in this study...
April 18, 2018: Environmental Toxicology
https://www.readbyqxmd.com/read/29666135/study-protocol-for-the-saron-trial-a-multicentre-randomised-controlled-phase-iii-trial-comparing-the-addition-of-stereotactic-ablative-radiotherapy-and-radical-radiotherapy-with-standard-chemotherapy-alone-for-oligometastatic-non-small-cell-lung-cancer
#13
John Conibear, Brendan Chia, Yenting Ngai, Andrew Tom Bates, Nicholas Counsell, Rushil Patel, David Eaton, Corinne Faivre-Finn, John Fenwick, Martin Forster, Gerard G Hanna, Susan Harden, Philip Mayles, Syed Moinuddin, David Landau
INTRODUCTION: Following growing evidence to support the safety, local control (LC) and potential improvement in overall survival (OS) in patients with oligometastatic non-small cell lung cancer (NSCLC) that have been treated with local ablative therapy such as stereotactic ablative radiotherapy (SABR) and stereotactic radiosurgery (SRS), we initiate the SARON trial to investigate the impact and feasibility of adding SABR/SRS and radical radiotherapy (RRT) following standard chemotherapy on OS...
April 17, 2018: BMJ Open
https://www.readbyqxmd.com/read/29666124/generation-of-a-double-binary-transgenic-zebrafish-model-to-study-myeloid-gene-regulation-in-response-to-oncogene-activation-in-melanocytes
#14
Amy Kenyon, Daria Gavriouchkina, Jernej Zorman, Vanessa Chong-Morrison, Giorgio Napolitani, Vincenzo Cerundolo, Tatjana Sauka-Spengler
A complex network of inflammatory genes is closely linked to somatic cell transformation and malignant disease. Immune cells and their associated molecules are responsible for detecting and eliminating cancer cells as they establish themselves as the precursors of a tumour. By the time a patient has a detectable solid tumour, cancer cells have escaped the initial immune response mechanisms. Here, we describe the development of a double binary zebrafish model that enables regulatory programming of the myeloid cells as they respond to oncogene-activated melanocytes to be explored, focussing on the initial phase when cells become the precursors of cancer...
April 6, 2018: Disease Models & Mechanisms
https://www.readbyqxmd.com/read/29666026/cervical-cancer-state-of-the-science-from-angiogenesis-blockade-to-checkpoint-inhibition
#15
REVIEW
Lindsey E Minion, Krishnansu S Tewari
Vascular endothelial growth factor (VEGF) has emerged as a therapeutic target in several malignancies, including cervical cancer. Chemotherapy doublets combined with the fully humanized monoclonal antibody, bevacizumab, now constitute first-line therapy for women struggling with recurrent/metastatic cervical carcinoma. Regulatory approval for this indication was based on the phase III randomized trial, GOG 240, which demonstrated a statistically significant and clinically meaningful improvement in overall survival when bevacizumab was added to chemotherapy: 17...
March 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29665670/-the-relationship-between-the-radioresistance-of-pancreatic-cancer-cell-sw1990-and-the-induction-of-the-epithelial-mesenchymal-transition-an-in-vitro-study
#16
Y H Jiang, K Y You, Z F Bi, L T Li, H Q Mo, Y M Liu
Objective: To investigate the relationship between the radioresistance of pancreatic cancer cell SW1990 and the induction of the Epithelial-Mesenchymal Transition (EMT). Methods: The radio-resistant pancreatic cancer cell SW1990-R were established by using the method of radiating pancreatic cancer cell SW1990 step by step and repeatedly. Then the changes of the morphology of the cell was observed by inverted phase contrast microscope, the radioresistance of SW1990-R was detected by colony-forming assay, and the apoptosis rate of the two cell lines after radiation were measured by flow cytometry...
March 27, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29665367/suppression-of-akt-mediated-hdac3-expression-and-cdk2-t39-phosphorylation-by-a-bichalcone-analog-contributes-to-s-phase-retardation-of-cancer-cells
#17
Kuang-Chen Hung, Meng-Liang Lin, Shih-Wei Hsu, Chuan-Chun Lee, Ren-Yu Huang, Tian-Shung Wu, Shih-Shun Chen
Targeting cell cycle regulators has been a suggested mechanism for therapeutic cancer strategies. We report here that the bichalcone analog TSWU-CD4 induces S phase arrest of human cancer cells by inhibiting the formation of cyclin A-phospho (p)-cyclin-dependent kinase 2 (CDK2, threonine [Thr] 39) complexes, independent of mutant p53 expression. Ectopic expression of CDK2 (T39E), which mimics phosphorylation of the Thr 39 residue of CDK2, partially rescues the cells from TSWU-CD4-induced S phase arrest, whereas phosphorylation-deficient CDK2 (T39A) expression regulates cell growth with significant S phase arrest and enhances TSWU-CD4-triggered S phase arrest...
April 14, 2018: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29664714/randomized-phase-ii-trial-of-fulvestrant-plus-everolimus-or-placebo-in-postmenopausal-women-with-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-metastatic-breast-cancer-resistant-to-aromatase-inhibitor-therapy-results-of-pre0102
#18
Noah Kornblum, Fengmin Zhao, Judith Manola, Paula Klein, Bhuvaneswari Ramaswamy, Adam Brufsky, Phillip J Stella, Brian Burnette, Melinda Telli, Della F Makower, Puneet Cheema, Cristina I Truica, Antonio C Wolff, Gamini S Soori, Barbara Haley, Timothy R Wassenaar, Lori J Goldstein, Kathy D Miller, Joseph A Sparano
Purpose The mammalian target of rapamycin inhibitor everolimus targets aberrant signaling through the PI3K/AKT/mammalian target of rapamycin pathway, a mechanism of resistance to anti-estrogen therapy in estrogen receptor (ER)-positive breast cancer. We hypothesized that everolimus plus the selective ER downregulator fulvestrant would be more efficacious than fulvestrant alone in ER-positive metastatic breast cancer resistant to aromatase inhibitor (AI) therapy. Patients and Methods This randomized, double-blind, placebo-controlled, phase II study included 131 postmenopausal women with ER-positive, human epidermal growth factor receptor 2-negative, AI-resistant metastatic breast cancer randomly assigned to fulvestrant (500 mg days 1 and 15 of cycle 1, then day 1 of cycles 2 and beyond) plus everolimus or placebo...
April 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29663679/the-role-of-cruciferous-vegetables-and-isothiocyanates-for-lung-cancer-prevention-current-status-challenges-and-future-research-directions
#19
REVIEW
Zhenzhen Zhang, Raymond Bergan, Jackilen Shannon, Christopher G Slatore, Gerd Bobe, Yumie Takata
Lung cancer remains a leading cause of cancer-related deaths in the United States. Although smoking and air pollution exposure are primary risk factors of lung cancer, diet has also been reported to contribute to lung cancer risk. Cruciferous vegetables contain many bioactive compounds that alter the detoxification process of air-borne carcinogenic compounds and, thereby, may decrease lung cancer risk. In our meta-analysis of 31 observational studies, cruciferous vegetable intake was inversely associated with lung cancer risk (summary odds ratio/relative risk = 0...
April 16, 2018: Molecular Nutrition & Food Research
https://www.readbyqxmd.com/read/29663662/glabridin-induces-apoptosis-and-cell-cycle-arrest-in-oral-cancer-cells-through-the-jnk1-2-signaling-pathway
#20
Chang-Tai Chen, Yi-Tzu Chen, Yi-Hsien Hsieh, Chia-Jui Weng, Jung-Chun Yeh, Shun-Fa Yang, Chiao-Wen Lin, Jia-Sin Yang
Glabridin, a flavonoid extracted from licorice (Glycyrrhiza glabra), possesses various biological properties, including anticancer activities. However, the effect of glabridin on oral cancer cell apoptosis and the underlying molecular mechanisms has not been elucidated. In this study, we demonstrated that glabridin treatment significantly inhibits cell proliferation in human oral cancer SCC-9 and SAS cell lines. Flow cytometric assays demonstrated that glabridin induced several features of apoptosis, such as sub-G1 phase cell increase and phosphatidylserine externalization...
April 16, 2018: Environmental Toxicology
keyword
keyword
17437
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"